Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide

Linhua Zhang,1 Yanqing Ren,2 Yong Wang,3 Yingna He,2 Wei Feng,2 Cunxian Song1 1Key Laboratory of Biomedical Material of Tianjin, Institute of Biomedical Engineering, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China; 2Hebei Key Laboratory of Chinese Medicine Resea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang L, Ren Y, Wang Y, He Y, Feng W, Song C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	liposome mitoxantrone luteinizing hormone-releasing hormone receptor tumor targeting gonadorelin. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3cc1f5f39b43406e808749095de877a5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3cc1f5f39b43406e808749095de877a5
record_format	dspace
spelling	oai:doaj.org-article:3cc1f5f39b43406e808749095de877a52021-12-02T04:52:09ZPharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide1178-2013https://doaj.org/article/3cc1f5f39b43406e808749095de877a52018-02-01T00:00:00Zhttps://www.dovepress.com/pharmacokinetics-distribution-and-anti-tumor-efficacy-of-liposomal-mit-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Linhua Zhang,1 Yanqing Ren,2 Yong Wang,3 Yingna He,2 Wei Feng,2 Cunxian Song1 1Key Laboratory of Biomedical Material of Tianjin, Institute of Biomedical Engineering, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China; 2Hebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease, Pharmaceutical College, Hebei University of Chinese Medicine, Shijiazhuang City, Hebei Province, China; 3Department of Physics and Chemistry, College of Medicine, Hebei University, Baoding City, Hebei Province, China Background: A previous study developed a novel luteinizing hormone-releasing hormone (LHRH) receptor-targeted liposome. The aim of this study was to further assess the pharmacokinetics, biodistribution, and anti-tumor efficacy of LHRH receptor-targeted liposomes loaded with the anticancer drug mitoxantrone (MTO). Methods: Plasma and tissue distribution profiles of LHRH receptor-targeted MTO-loaded liposomes (LHRH-MTO-LIPs) were quantified in healthy mice or a xenograft tumor nude mouse model of MCF-7 breast cancer, and were compared with non-targeted liposomes and a free-drug solution. Results: The LHRH-MTO-LIPs demonstrated a superior pharmacokinetic profile relative to free MTO. The first target site of accumulation is the kidney, followed by the liver, and then the tumor; maximal tumor accumulation occurs at 4 h post-administration. Moreover, the LHRH-MTO-LIPs exhibited enhanced inhibition of MCF-7 breast cancer cell growth in vivo compared with non-targeted MTO-loaded liposomes (MTO-LIPs) and free MTO. Conclusion: The novel LHRH receptor-targeted liposome may become a viable platform for the future targeted treatment of cancer. Keywords: liposome, mitoxantrone, luteinizing hormone-releasing hormone receptor, tumor targeting, gonadorelinZhang LRen YWang YHe YFeng WSong CDove Medical Pressarticleliposomemitoxantroneluteinizing hormone-releasing hormone receptortumor targetinggonadorelin.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 1097-1105 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	liposome mitoxantrone luteinizing hormone-releasing hormone receptor tumor targeting gonadorelin. Medicine (General) R5-920
spellingShingle	liposome mitoxantrone luteinizing hormone-releasing hormone receptor tumor targeting gonadorelin. Medicine (General) R5-920 Zhang L Ren Y Wang Y He Y Feng W Song C Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
description	Linhua Zhang,1 Yanqing Ren,2 Yong Wang,3 Yingna He,2 Wei Feng,2 Cunxian Song1 1Key Laboratory of Biomedical Material of Tianjin, Institute of Biomedical Engineering, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China; 2Hebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease, Pharmaceutical College, Hebei University of Chinese Medicine, Shijiazhuang City, Hebei Province, China; 3Department of Physics and Chemistry, College of Medicine, Hebei University, Baoding City, Hebei Province, China Background: A previous study developed a novel luteinizing hormone-releasing hormone (LHRH) receptor-targeted liposome. The aim of this study was to further assess the pharmacokinetics, biodistribution, and anti-tumor efficacy of LHRH receptor-targeted liposomes loaded with the anticancer drug mitoxantrone (MTO). Methods: Plasma and tissue distribution profiles of LHRH receptor-targeted MTO-loaded liposomes (LHRH-MTO-LIPs) were quantified in healthy mice or a xenograft tumor nude mouse model of MCF-7 breast cancer, and were compared with non-targeted liposomes and a free-drug solution. Results: The LHRH-MTO-LIPs demonstrated a superior pharmacokinetic profile relative to free MTO. The first target site of accumulation is the kidney, followed by the liver, and then the tumor; maximal tumor accumulation occurs at 4 h post-administration. Moreover, the LHRH-MTO-LIPs exhibited enhanced inhibition of MCF-7 breast cancer cell growth in vivo compared with non-targeted MTO-loaded liposomes (MTO-LIPs) and free MTO. Conclusion: The novel LHRH receptor-targeted liposome may become a viable platform for the future targeted treatment of cancer. Keywords: liposome, mitoxantrone, luteinizing hormone-releasing hormone receptor, tumor targeting, gonadorelin
format	article
author	Zhang L Ren Y Wang Y He Y Feng W Song C
author_facet	Zhang L Ren Y Wang Y He Y Feng W Song C
author_sort	Zhang L
title	Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
title_short	Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
title_full	Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
title_fullStr	Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
title_full_unstemmed	Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
title_sort	pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/3cc1f5f39b43406e808749095de877a5
work_keys_str_mv	AT zhangl pharmacokineticsdistributionandantitumorefficacyofliposomalmitoxantronemodifiedwithaluteinizinghormonereleasinghormonereceptorspecificpeptide AT reny pharmacokineticsdistributionandantitumorefficacyofliposomalmitoxantronemodifiedwithaluteinizinghormonereleasinghormonereceptorspecificpeptide AT wangy pharmacokineticsdistributionandantitumorefficacyofliposomalmitoxantronemodifiedwithaluteinizinghormonereleasinghormonereceptorspecificpeptide AT hey pharmacokineticsdistributionandantitumorefficacyofliposomalmitoxantronemodifiedwithaluteinizinghormonereleasinghormonereceptorspecificpeptide AT fengw pharmacokineticsdistributionandantitumorefficacyofliposomalmitoxantronemodifiedwithaluteinizinghormonereleasinghormonereceptorspecificpeptide AT songc pharmacokineticsdistributionandantitumorefficacyofliposomalmitoxantronemodifiedwithaluteinizinghormonereleasinghormonereceptorspecificpeptide
_version_	1718400999858634752

Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide

Ejemplares similares